Ariad Reports Upbeat Trial Results
Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) reported upbeat initial results from an advanced blood cancer treatment sending the stock price soaring 72 cents to close at $2.45.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.